WO2004070051A3 - Chemical proteomics - Google Patents

Chemical proteomics Download PDF

Info

Publication number
WO2004070051A3
WO2004070051A3 PCT/US2003/003320 US0303320W WO2004070051A3 WO 2004070051 A3 WO2004070051 A3 WO 2004070051A3 US 0303320 W US0303320 W US 0303320W WO 2004070051 A3 WO2004070051 A3 WO 2004070051A3
Authority
WO
WIPO (PCT)
Prior art keywords
identification
drugs
drug candidates
new
technology
Prior art date
Application number
PCT/US2003/003320
Other languages
French (fr)
Other versions
WO2004070051A2 (en
Inventor
Shane Climie
Leroi Victor Desouza
Henry S Duewel
Christopher Mark Hosfield
Linda Chiou-Lin Liao
Linda D B Mcbroom
Irving Sucholeiki
Leticia M Toledo-Sherman
Original Assignee
Mds Proteomics Inc
Shane Climie
Leroi Victor Desouza
Henry S Duewel
Christopher Mark Hosfield
Linda Chiou-Lin Liao
Linda D B Mcbroom
Irving Sucholeiki
Leticia M Toledo-Sherman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mds Proteomics Inc, Shane Climie, Leroi Victor Desouza, Henry S Duewel, Christopher Mark Hosfield, Linda Chiou-Lin Liao, Linda D B Mcbroom, Irving Sucholeiki, Leticia M Toledo-Sherman filed Critical Mds Proteomics Inc
Priority to PCT/US2003/003320 priority Critical patent/WO2004070051A2/en
Priority to AU2003214993A priority patent/AU2003214993A1/en
Publication of WO2004070051A2 publication Critical patent/WO2004070051A2/en
Publication of WO2004070051A3 publication Critical patent/WO2004070051A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

The invention relates to methods and reagents for identifying/isolating protein targets of chemical compounds (for example, drug candidates) using mass spectrometry. The invention provides a method for capturing and identifying proteins using tethered small-molecule probes. This technology also allows the market expansion of known drugs by finding new therapeutic targets; identification of the mechanism of toxicity of drug candidates or drugs which failed in the clinic; identification of new chemical tools for chemically-driven target validation; identification of new drug leads; and identification of the mechanism of action of drugs and drug candidates. A key advantage of the technology is that a single experiment can identify the numerous proteins which interact with a probe (or 'bait').
PCT/US2003/003320 2003-02-03 2003-02-03 Chemical proteomics WO2004070051A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US2003/003320 WO2004070051A2 (en) 2003-02-03 2003-02-03 Chemical proteomics
AU2003214993A AU2003214993A1 (en) 2003-02-03 2003-02-03 Chemical proteomics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/003320 WO2004070051A2 (en) 2003-02-03 2003-02-03 Chemical proteomics

Publications (2)

Publication Number Publication Date
WO2004070051A2 WO2004070051A2 (en) 2004-08-19
WO2004070051A3 true WO2004070051A3 (en) 2005-02-24

Family

ID=32848674

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/003320 WO2004070051A2 (en) 2003-02-03 2003-02-03 Chemical proteomics

Country Status (2)

Country Link
AU (1) AU2003214993A1 (en)
WO (1) WO2004070051A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7537807B2 (en) 2003-09-26 2009-05-26 Cornell University Scanned source oriented nanofiber formation
US7622273B2 (en) * 2005-05-11 2009-11-24 Gibbs Bernard F Method for chemical and enzymatic treatment of posttranslationally modified proteins bound to a protein chip
CN110658314B (en) * 2019-10-12 2021-06-29 四川大学 Method for identifying target of compound, method for detecting interaction between compound and target, and method for evaluating drug effect of compound

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585277A (en) * 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
US5780307A (en) * 1988-12-02 1998-07-14 Soldin; Steven J. Immunosuppressive drug binding proteins and use
US5939021A (en) * 1997-01-23 1999-08-17 Hansen; W. Peter Homogeneous binding assay
US6197599B1 (en) * 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780307A (en) * 1988-12-02 1998-07-14 Soldin; Steven J. Immunosuppressive drug binding proteins and use
US5585277A (en) * 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
US5939021A (en) * 1997-01-23 1999-08-17 Hansen; W. Peter Homogeneous binding assay
US6197599B1 (en) * 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins

Also Published As

Publication number Publication date
AU2003214993A8 (en) 2004-08-30
AU2003214993A1 (en) 2004-08-30
WO2004070051A2 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
Rand et al. Measuring the hydrogen/deuterium exchange of proteins at high spatial resolution by mass spectrometry: overcoming gas-phase hydrogen/deuterium scrambling
Wilson et al. Proteomic analysis of fatty-acylated proteins in mammalian cells with chemical reporters reveals S-acylation of histone H3 variants
VerBerkmoes et al. Integrating “top-down” and “bottom-up” mass spectrometric approaches for proteomic analysis of Shewanella oneidensis
Beaudette et al. Proteomic techniques to probe the ubiquitin landscape
Matheron et al. Characterization of biases in phosphopeptide enrichment by Ti4+-immobilized metal affinity chromatography and TiO2 using a massive synthetic library and human cell digests
Smith et al. O-linked glycosylation sites profiling in Mycobacterium tuberculosis culture filtrate proteins
WO2001018252A3 (en) Methods for disease detection
WO2004092708A3 (en) Methods for the electrochemical detection of target compounds
WO2006128138A3 (en) Biodetection by nucleic acid-templated chemistry
WO2007030571A3 (en) Identification of targets and development of reagents for testing and molecular imaging of human disease
Zhu et al. Residue-specific mass signatures for the efficient detection of protein modifications by mass spectrometry
WO2001042502A3 (en) Methods for disease detection
EP2298814A3 (en) Method for quantifying phosphokinase activity on proteins
Ritzefeld et al. New developments in probing and targeting protein acylation in malaria, leishmaniasis and African sleeping sickness
DE60233870D1 (en) PEPTIDFRAGMENTATION
Harris et al. On-probe digestion of bacterial proteins for MALDI-MS
WO2009061904A8 (en) MASS SPECTROMETRY ASSAY FOR eIF4E AND eIF4E REGULON ACTIVITY
Pels et al. DNA-compatible solid-phase combinatorial synthesis of β-cyanoacrylamides and related electrophiles
Pashkova et al. Coumarin tags for analysis of peptides by MALDI-TOF MS and MS/MS. 2. Alexa Fluor 350 tag for increased peptide and protein identification by LC-MALDI-TOF/TOF MS
Hess The emerging field of chemo‐and pharmacoproteomics
WO2002093129A3 (en) Methods for analyzing interactions between proteins in live and intact cells
Renuse et al. Signature fragment ions of biotinylated peptides
SE0001670D0 (en) Mass spectrometry-based biosensor
Chicooree et al. A novel approach to the analysis of SUMOylation with the independent use of trypsin and elastase digestion followed by database searching utilising consecutive residue addition to lysine
WO2004070051A3 (en) Chemical proteomics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP